The University of Edinburgh
Novel regulators and inhibitors of aortic valve calcification
Abstract
dc:description.abstractOBJECTIVE: Activation and transformation of aortic valvular interstitial cells (VICs) are implicated in the pathogenesis of severe calcific aortic stenosis (CAS). Our aim was to characterise gene expression pathways of CAS in porcine VICs and to determine the in vitro effects of a novel inhibitor of calcification. BACKGROUND: CAS is a common condition well extended in the general population and affecting 2-4% of 65 year old people. The treatment consists of watchful waiting and surgical valve replacement when patients become symptomatic. There are marked inter-individual variations which will influence patients‟ progress from aortic sclerosis to aortic stenosis with clinical symptoms as well as the speed at which aortic stenosis progresses in a given patient. The spectrum of severity from CAS may get worse as it progresses. Furthermore, 25% of patients over 65 years of age will develop symptoms linked to moderate or severe AS. The prognosis is reasonably good until symptoms appear. Then it is poor, with two years survival rate of roughly 50%. Currently there is still no medical therapy capable of stopping the progression of the disease and there are no methods of predicting the rate of progression. METHODS: In vitro calcification studies were undertaken using porcine VICs. Calcification was induced with 3 mM sodium phosphate (Na3PO4), pH 7.4, and the effect of Denosumab (inhibitor of Receptor Activator of Nuclear factor K-B Ligand, RANKL) at a working concentration of 50μg/mL was analysed. mRNA expression of osteoblast and myofibroblast markers were measured by quantitative polymerase chain reaction (qPCR). Calcification was determined by Alizarin Red staining and alkaline phosphatase (ALP) activity. Cell growth rate was determined by Roche ExCelligence technology. RESULTS: Initial studies demonstrated that porcine VICs calcify spontaneously with demonstrable calcium deposition by day 14 (376.7% increase; p<0.001), associated with a progressive 3-fold increase in ALP activity (p<0.05). Analysis of mRNA by qPCR during this process showed significant changes in a number of genetic markers of VIC cell trans-differentiation through myofibroblast to osteoblasts. -Actin, a marker of myoblast phenotype, presented a 1.7 fold growth by day 14; P<0.05. Additionally, expression of the osteoblast marker: Runx2 showed an increase of 1.3 fold by day 14; P<0.05 and TGF-, a promoter of osteogenesis, expressed an upward trend with a peak of 3.2 fold by day 14; P<0.001. RhoA turned out to be a regulator of nodule formation in myoblasts, and it revealed an increase of 4.6 fold; P<0.001. Finally, RANKL mRNA expression remained unchanged and calponin, an inhibitor of bone formation in osteoblasts, presented a decrease by day 14 of 0.7 fold; P<0.05. Treatment of porcine VICs with Na3PO4 led to a marked increase in calcium deposition (535%; P<0.05). Denosumab dramatically inhibited this Na3PO4 induced calcification to baseline levels (P<0.05) but had no significant effect on ALP activity when compared to Na3PO4 treated cells. Following 6 days of treatment with Denosumab at 50 μg/ml, there was no significant difference in VICs growth rate in either untreated cells or NaPi treated cells. CONCLUSION: It is possible to conclude that porcine VICs are a good model to study the process of CAS. This study has demonstrated the upregulation of key molecules during the spontaneous calcification of VICs with an increase of Calcium, Collagen and ALP activity. The cells expressed markers for both vascular smooth muscle cells and osteoblasts, suggesting a transdifferentiation of the phenotype. Upregulation of α-Actin, Runx2, TGF-β and RhoA and downregulation of Calponin were noted, with no changes seen in RANKL expression. Calcification of VICs can be increased by the addition of NaPi 3mM and TGFβ10 ng/ml + NaPi 3mM. Denosumab inhibited induced calcification to baseline with no toxic effect on cells. A fuller understanding of the actions of Denosumab may identify a novel therapeutic strategy for clinical intervention against aortic valve calcification and aortic stenosis.
Degree
thesis:*- Grantor dc:publisher
- The University of Edinburgh
- Year dc:date.issued
- 2012
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Lerman, Daniel
- Advisor dc:contributor.advisor
-
- Macrae, Vicky
Subjects
dc:subject × 1Rights
- Language dc:language.iso
- en
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- http://hdl.handle.net/1842/11680